ES2185153T3 - Uso de mefloquina(+) para el tratamiento de la malaria. - Google Patents

Uso de mefloquina(+) para el tratamiento de la malaria.

Info

Publication number
ES2185153T3
ES2185153T3 ES98910836T ES98910836T ES2185153T3 ES 2185153 T3 ES2185153 T3 ES 2185153T3 ES 98910836 T ES98910836 T ES 98910836T ES 98910836 T ES98910836 T ES 98910836T ES 2185153 T3 ES2185153 T3 ES 2185153T3
Authority
ES
Spain
Prior art keywords
quinolinemethanol
piperidinyl
trifluoromethyl
alpha
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98910836T
Other languages
English (en)
Inventor
Robin Shepherd
Allan Fletcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704809.4A external-priority patent/GB9704809D0/en
Priority claimed from GBGB9722232.7A external-priority patent/GB9722232D0/en
Priority claimed from GBGB9724263.0A external-priority patent/GB9724263D0/en
Priority claimed from GBGB9724712.6A external-priority patent/GB9724712D0/en
Application filed by Vernalis Research Ltd filed Critical Vernalis Research Ltd
Application granted granted Critical
Publication of ES2185153T3 publication Critical patent/ES2185153T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE PRESENTA LA UTILIZACION DE (+)-(11R,2''S)- AL -2-PIPERIDINIL2,8-BIS(TRIFLUOROMETIL)-4-QUINOLINAMETANOL O UNA SAL FARMACOLOGICAMENTE ACEPTABLE DEL MISMO BASICAMENTE LIBRE DE SU (-)ENANTIOMERO PARA LA FABRICACION DE UN MEDICAMENTO QUE TIENE EFECTOS COLATERALES REDUCIDOS EN COMPARACION CON EL ( (MAS MENOS) )-(R * , S * )- AL -2-PIPERIDINIL-2,8-BIS(TRIFLUOROMETIL)-4QUINOLINAMETANOL RACEMICO PARA EL TRATAMIENTO O LA PREVENCION DE LA MALARIA EN UN SUJETO. TAMBIEN SE PRESENTA UN PROCEDIMIENTO PARA TRATAR O PREVENIR LA MALARIA CON EFECTOS COLATERALES REDUCIDOS QUE COMPRENDE LA ADMINISTRACION DE (+)-(11R,2''S)- AL -2-PIPERIDINIL2,8-BIS(TRIFLUOROMETIL)-4-QUINOLINAMETANOL O DE UNA SAL FARMACOLOGICAMENTE ACEPTABLE DEL MISMO BASICAMENTE LIBRE DE SU (-)- ENANTIOMERO.
ES98910836T 1997-03-07 1998-03-06 Uso de mefloquina(+) para el tratamiento de la malaria. Expired - Lifetime ES2185153T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9704809.4A GB9704809D0 (en) 1997-03-07 1997-03-07 Chemical compounds
GBGB9722232.7A GB9722232D0 (en) 1997-10-21 1997-10-21 Chemical compounds
GBGB9724263.0A GB9724263D0 (en) 1997-11-17 1997-11-17 Chemical compounds
GBGB9724712.6A GB9724712D0 (en) 1997-11-21 1997-11-21 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2185153T3 true ES2185153T3 (es) 2003-04-16

Family

ID=27451612

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98910836T Expired - Lifetime ES2185153T3 (es) 1997-03-07 1998-03-06 Uso de mefloquina(+) para el tratamiento de la malaria.

Country Status (10)

Country Link
US (1) US6664397B1 (es)
EP (1) EP0966285B1 (es)
JP (1) JP4380800B2 (es)
AT (1) ATE225177T1 (es)
AU (1) AU730818B2 (es)
DE (1) DE69808440T2 (es)
DK (1) DK0966285T3 (es)
ES (1) ES2185153T3 (es)
PT (1) PT966285E (es)
WO (1) WO1998039003A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026627A1 (en) * 1997-11-26 1999-06-03 Cerebrus Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
GB0021776D0 (en) 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
GB0406014D0 (en) * 2004-03-17 2004-04-21 Arakis Ltd Pharmaceutical composition and use
WO2006138487A2 (en) * 2005-06-14 2006-12-28 The Johns Hopkins University Treatment of ischemia-induced arrhythmias
CN101466380A (zh) * 2006-02-16 2009-06-24 麦克莱恩医院 治疗帕金森病的方法和组合物
US20110039888A1 (en) * 2008-04-21 2011-02-17 Coltart Don M Asymmetric alpha functionalization and alpha, alpha bisfunctionalization of aldehydes and ketones
CN102481282A (zh) * 2009-03-24 2012-05-30 新加坡国立大学 青蒿素衍生物用于治疗哮喘和慢性阻塞性肺病(copd)的用途
WO2012068560A2 (en) 2010-11-18 2012-05-24 Jenrin Discovery 4-quinolinemethanols as anti-malarial agents
EP2487157A1 (en) 2011-02-11 2012-08-15 Université de Picardie Jules Verne Enantioselective synthesis method of 4-aminoalcoholquinoline derivatives and the use
RU2015105407A (ru) 2012-08-09 2016-10-10 Кэн-Файт Биофарма Лтд. Лиганды аденозинового рецептора а3 для применения при лечении половой дисфункции
CN103304538B (zh) * 2013-06-21 2014-12-24 中国人民解放军第四军医大学 右旋甲氟喹的合成
CN107149601B (zh) * 2017-05-25 2020-04-17 中国中医科学院中药研究所 青蒿素类化合物在制备治疗神经病理性疼痛和/或并发症的药物中的应用
US11220482B2 (en) 2017-11-03 2022-01-11 Universite Amiens Picardie Jules Verne Aminopyridinemethanol compounds and their use
CN110507646A (zh) * 2019-09-12 2019-11-29 广州中医药大学(广州中医药研究院) 青蒿素衍生物在制备抗焦虑症的药物或缓解焦虑症的食品中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE2940443A1 (de) 1979-10-05 1981-04-16 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von erythro-(alpha)-2-piperidyl-2,8-bis-(trifluormethyl)-4-chinolin-methanol
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system

Also Published As

Publication number Publication date
ATE225177T1 (de) 2002-10-15
JP2001526637A (ja) 2001-12-18
HK1024631A1 (en) 2000-10-20
JP4380800B2 (ja) 2009-12-09
AU6506898A (en) 1998-09-22
EP0966285A1 (en) 1999-12-29
AU730818B2 (en) 2001-03-15
DE69808440D1 (de) 2002-11-07
US6664397B1 (en) 2003-12-16
PT966285E (pt) 2002-12-31
EP0966285B1 (en) 2002-10-02
WO1998039003A1 (en) 1998-09-11
DK0966285T3 (da) 2002-10-28
DE69808440T2 (de) 2003-07-10

Similar Documents

Publication Publication Date Title
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
ATE399171T1 (de) Camptothecinanaloge und deren zubereitungsmethoden
EA200801806A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
PT966285E (pt) Utilizacao de (+)mefloquina para o tratamento da malaria
DK0998287T3 (da) Anvendelse af levobupivacain
EE05315B1 (et) Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette n„htud imetajal esineva seksuaalse funktsioonih„ire ravimiseks v?i m?jutamiseks
WO2000071108A3 (en) Methods for treatment of asthma using s-oxybutynin
SE9903997D0 (sv) New compounds
GEP20043162B (en) Derivatives of Isosorbid Mononitrate, Utilization as Vasodilator Agents with Reduced Tolerance
CA2283255A1 (en) Use of r-nsaid's for the prevention of alzheimer's disease
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
SE9900070D0 (sv) New use
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
GEP20063754B (en) Quinoline Derivatives and Use Thereof as Antitumor Agents
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
DK0378146T3 (da) Polyamin-derivater som antineoplastiske midler
EA200300430A1 (ru) Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин